Literature DB >> 11086057

Peptide-MHC class I tetrameric complexes display exquisite ligand specificity.

S R Burrows1, N Kienzle, A Winterhalter, M Bharadwaj, J D Altman, A Brooks.   

Abstract

The production of synthetic MHC-peptide tetramers has revolutionized cellular immunology by revealing enormous CD8(+) T cell expansions specific for peptides from various pathogens. A feature of these reagents, essential for their staining function, is that they bind T cells with relatively high avidity. This could, theoretically, promote cross-reactivity with irrelevant T cells leading to overestimates of epitope-specific T cell numbers. Therefore, we have investigated the fine specificity of CTL staining with these reagents for comparison with functional data. Using a panel of CTL clones with distinct fine specificity patterns for analogs of an HLA-B8-binding EBV epitope, together with B8 tetramers incorporating these peptides, we show a very good correlation between tetramer staining and peptide activity in cytotoxicity assays. Significant staining only occurred with tetramers that incorporate strong stimulatory agonist peptides and not weak agonists that are unlikely to induce full T cell activation at physiological levels of presentation. In almost every case where a peptide analog had >10-fold less activity than the optimal EBV peptide in cytotoxicity assays, the corresponding tetramer stained with >10-fold less intensity than the EBV epitope tetramer. Furthermore, by examining an EBV-specific clonotypic T cell expansion in EBV-exposed individuals, we show similar fine specificity in tetramer staining of fresh peripheral T cells. Collectively, our data demonstrate the exquisite specificity of class I MHC-peptide tetramers, underlining their accuracy in quantifying only those T cells capable of recognizing the low levels of cell surface peptide presented after endogenous Ag processing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086057     DOI: 10.4049/jimmunol.165.11.6229

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.

Authors:  V Rubio-Godoy; V Dutoit; D Rimoldi; D Lienard; F Lejeune; D Speiser; P Guillaume; J C Cerottini; P Romero; D Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Authors:  Marleen M van Loenen; Renate de Boer; Avital L Amir; Renate S Hagedoorn; Gerdien L Volbeda; Roelof Willemze; Johannes J van Rood; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

3.  Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement.

Authors:  Samantha E Kerry; Jennifer Buslepp; Lorraine A Cramer; Robert Maile; Lucinda L Hensley; Alma I Nielsen; Paula Kavathas; Barbara J Vilen; Edward J Collins; Jeffrey A Frelinger
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

4.  IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

Authors:  SangKon Oh; Liyanage P Perera; Donald S Burke; Thomas A Waldmann; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

5.  Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability.

Authors:  Scott R Burrows; Zhenjun Chen; Julia K Archbold; Fleur E Tynan; Travis Beddoe; Lars Kjer-Nielsen; John J Miles; Rajiv Khanna; Denis J Moss; Yu Chih Liu; Stephanie Gras; Lyudmila Kostenko; Rebekah M Brennan; Craig S Clements; Andrew G Brooks; Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

6.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

7.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Authors:  Björn de Rijke; Agnes van Horssen-Zoetbrood; Jeffrey M Beekman; Britt Otterud; Frans Maas; Rob Woestenenk; Michel Kester; Mark Leppert; Anton V Schattenberg; Theo de Witte; Elly van de Wiel-van Kemenade; Harry Dolstra
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

8.  Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

Authors:  Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

9.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

10.  Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation.

Authors:  Pim L J van der Heiden; Renate de Boer; Dirk M van der Steen; Michel G D Kester; Menno W A G van der Hoorn; Wilmy M E Haarman; Helen E Barnby-Porritt; Jeremy W Fry; C E Napper; Erik W A Marijt; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.